ResearcherUniversity of Nebraska Medical CenterNo recent work listed

Richard S. Laschanzky

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-5480-6654; OpenAlex author ID A5061658150. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 6

Papers, trials and grants by year

2019: 1 paper

Papers 1

Selective Inhibition of Histone Deacetylases 1/2/6 in Combination with Gemcitabine: A Promising Combination for Pancreatic Cancer Therapy. Co-author DOI 10.3390/cancers11091327 ↗

Closest collaborators

The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Jennifer D. Black · 1 shared paper, 2019 · strength 0.08
- Paper Selective Inhibition of Histone Deacetylases 1/2/6 in Combination with Gemcitabine: A Promising Combination for Pancrea… DOI 10.3390/cancers11091327 ↗
Aneesha Dasgupta · 1 shared paper, 2019 · strength 0.08
- Paper Selective Inhibition of Histone Deacetylases 1/2/6 in Combination with Gemcitabine: A Promising Combination for Pancrea… DOI 10.3390/cancers11091327 ↗
Lynette M. Smith · 1 shared paper, 2019 · strength 0.08
- Paper Selective Inhibition of Histone Deacetylases 1/2/6 in Combination with Gemcitabine: A Promising Combination for Pancrea… DOI 10.3390/cancers11091327 ↗
Michael G Brattain · 1 shared paper, 2019 · strength 0.08
- Paper Selective Inhibition of Histone Deacetylases 1/2/6 in Combination with Gemcitabine: A Promising Combination for Pancrea… DOI 10.3390/cancers11091327 ↗
Pankaj Kumar Singh · 1 shared paper, 2019 · strength 0.08
- Paper Selective Inhibition of Histone Deacetylases 1/2/6 in Combination with Gemcitabine: A Promising Combination for Pancrea… DOI 10.3390/cancers11091327 ↗
Surendra Kumar Shukla · 1 shared paper, 2019 · strength 0.08
- Paper Selective Inhibition of Histone Deacetylases 1/2/6 in Combination with Gemcitabine: A Promising Combination for Pancrea… DOI 10.3390/cancers11091327 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.